trial · primary record
Bortezomib Injection
Myeloma
| Phase | Phase 2 |
|---|---|
| Status | TERMINATED |
| Sponsor | Unknown |
| Enrolment | 39 |
| Primary completion | 2026-08-31 |
| Primary endpoint | Number of patients able to self-administer |
| Registry ID | NCT04268199 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T13:41:10.307Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT04268199
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.